ANGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AngioDynamics Inc (ANGO) is not a strong buy at the moment for a beginner investor with a long-term perspective. While the company has positive developments in its NanoKnife System and a growing market for its technology, the financial performance shows declining net income and EPS. Technical indicators are moderately bullish, but no strong trading signals are present. Given the lack of significant trading trends, neutral sentiment from hedge funds and insiders, and no recent congressional trading data, it is better to hold off on investing until clearer positive financial or trading signals emerge.
The MACD is positive at 0.112, indicating a bullish trend, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). RSI is neutral at 71.627, and the stock is trading near its pivot level of 11.302 with resistance at 11.642 and support at 10.962. Overall, the technical indicators suggest moderate bullishness but no strong buy signal.
Expanded indications for NanoKnife System in Europe, enhancing treatment options for cancer patients.
Rising demand for minimally invasive treatments and increasing clinical evidence supporting IRE technology.
Launch of LIVER-IRE Global Registry to gather real-world clinical data.
Declining net income (-40.86% YoY) and EPS (-42.31% YoY) in the latest quarter.
No significant trading trends from hedge funds or insiders.
Lack of recent congressional trading data or strong trading sentiment.
In 2026/Q2, revenue increased by 9.04% YoY to $79.43M, and gross margin improved to 53.05%. However, net income dropped by 40.86% YoY to -$6.35M, and EPS fell by 42.31% YoY to -0.15, indicating profitability challenges.
No data available for analyst ratings or price target changes.
